Balance Sheet

Cash Flow Statement

Amortization Amortization Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Change in Working Capital Change in Working Capital Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Legend Biotech (LEGN) Cash from Operations (2019 - 2025)

Legend Biotech filings provide 7 years of Cash from Operations readings, the most recent being 12200000.0 for Q4 2025.

On a quarterly basis, Cash from Operations rose 85.14% to 12200000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 100195000.0, a 30.45% increase, with the full-year FY2025 number at 100200000.0, up 30.42% from a year prior.
Cash from Operations hit 12200000.0 in Q4 2025 for Legend Biotech, down from 28801000.0 in the prior quarter.
In the past five years, Cash from Operations ranged from a high of 28801000.0 in Q3 2025 to a low of 198465000.0 in Q4 2021.
Median Cash from Operations over the past 5 years was 59228500.0 (2021), compared with a mean of 58313050.0.
Biggest five-year swings in Cash from Operations: tumbled 13084.86% in 2023 and later surged 137.99% in 2025.
Legend Biotech's Cash from Operations stood at 198465000.0 in 2021, then skyrocketed by 74.94% to 49742000.0 in 2022, then tumbled by 92.28% to 95645000.0 in 2023, then increased by 14.16% to 82100000.0 in 2024, then skyrocketed by 85.14% to 12200000.0 in 2025.
The last three reported values for Cash from Operations were 12200000.0 (Q4 2025), 28801000.0 (Q3 2025), and 13042000.0 (Q2 2025) per Business Quant data.